CHA
ABBV icon

Carmichael Hill & Associates’s AbbVie ABBV Stock Holding History

Carmichael Hill & Associates’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$1.34M Buy
6,760
+71
+1% +$13.3K 0.47% 48
2024
Q2 		$1.15M Buy
6,689
+13
+0.2% +$2.15K 0.45% 50
2024
Q1 		$1.22M Buy
6,676
+12
+0.2% +$2.07K 0.48% 51
2023
Q4 		$1.03M Buy
6,664
+14
+0.2% +$2.04K 0.43% 57
2023
Q3 		$991K Buy
6,650
+13
+0.2% +$1.91K 0.46% 55
2023
Q2 		$894K Buy
6,637
+1,213
+22% +$178K 0.4% 59
2023
Q1 		$864K Buy
5,424
+134
+3% +$20.5K 0.42% 57
2022
Q4 		$855K Sell
5,290
-3
-0.1% -$460 0.44% 52
2022
Q3 		$710K Buy
5,293
+11
+0.2% +$1.58K 0.38% 61
2022
Q2 		$809K Sell
5,282
-991
-16% -$151K 0.42% 55
2022
Q1 		$1.02M Buy
6,273
+1,094
+21% +$159K 0.47% 47
2021
Q4 		$701K Buy
5,179
+36
+0.7% +$4.25K 0.31% 68
2021
Q3 		$555K Buy
5,143
+12
+0.2% +$1.37K 0.28% 79
2021
Q2 		$578K Buy
5,131
+21
+0.4% +$2.37K 0.29% 71
2021
Q1 		$553K Buy
5,110
+34
+0.7% +$3.64K 0.3% 71
2020
Q4 		$544K Buy
5,076
+694
+16% +$66.7K 0.32% 66
2020
Q3 		$384K Buy
4,382
+267
+6% +$25.1K 0.26% 82
2020
Q2 		$404K Buy
4,115
+580
+16% +$51.1K 0.3% 74
2020
Q1 		$269K Buy
3,535
+126
+4% +$10.7K 0.24% 86
2019
Q4 		$302K Sell
3,409
-73
-2% -$6.06K 0.21% 94
2019
Q3 		$264K Sell
3,482
-319
-8% -$21.9K 0.26% 88
2019
Q2 		$276K Sell
3,801
-62
-2% -$4.87K 0.27% 90
2019
Q1 		$311K Sell
3,863
-97
-2% -$7.93K 0.32% 81
2018
Q4 		$365K Sell
3,960
-113
-3% -$9.94K 0.42% 70
2018
Q3 		$385K Buy
4,073
+2
+0% +$190 0.37% 74
2018
Q2 		$377K Buy
4,071
+2
+0% +$195 0.41% 70
2018
Q1 		$385K Buy
4,069
+2
+0% +$220 0.42% 69
2017
Q4 		$393K Buy
+4,067
New +$383K 0.43% 71

Other funds holding ABBV

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

Carmichael Hill & Associates's ABBV Position: Q3 2024 in Review

Carmichael Hill & Associates increased its AbbVie (ABBV) stake by 1.1% in Q3 2024, buying an estimated $13.3K and bringing the position to 6,760 shares worth $1.34M. The position accounts for 0.47% of the portfolio, ranked #48.

Carmichael Hill & Associates first reported a position in ABBV in Q4 2017 and has held it in 28 quarters since. 3,498 funds tracked by Wall St. Rank hold ABBV as of Q3 2024.

  • Carmichael Hill & Associates held 6,760 shares of AbbVie worth $1.34M as of Q3 2024.
  • Carmichael Hill & Associates bought 71 AbbVie shares in Q3 2024, an estimated $13.3K.
  • AbbVie made up 0.47% of Carmichael Hill & Associates's portfolio in Q3 2024, its #48 holding.
  • Carmichael Hill & Associates first reported a position in AbbVie in Q4 2017 and has held it in 28 quarters since.
  • 3,498 funds tracked by Wall St. Rank held AbbVie as of Q3 2024.

Based on Carmichael Hill & Associates's 13F filing for Q3 2024, filed 29 Oct 2024.